MaxCyte Cash Flow Statement
NASDAQ: MXCTHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
1.37+0.09 (+7.03%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MaxCyte free cash flow
In fiscal 2025, MaxCyte generated -$34.4 million of operating cash flow and spent $1.8 million on capital expenditures. That left free cash flow of -$36.2 million, a free-cash-flow margin of -109.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
MaxCyte cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Net Income | -44.63M | -41.05M | -37.92M | -23.57M | -19.08M | -11.82M | -12.89M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| Depreciation & Amortization | 4.34M | 4.32M | 4.17M | 2.70M | 1.42M | 1.05M | 613.50K |
| Stock-Based Compensation | 9.21M | 13.08M | 13.98M | 11.75M | 7.96M | 2.47M | 1.75M |
| Change in Working Capital | 954.00K | 6.16M | 8.09M | -7.01M | 3.61M | 2.38M | 3.32M |
| Operating Cash Flow | -34.41M | -27.61M | -21.69M | -14.78M | -10.68M | -8.78M | -8.80M |
| Capital Expenditures | -1.77M | -1.65M | -3.70M | -18.48M | -3.83M | -2.07M | -1.27M |
| Investing Cash Flow | 25.93M | 6.93M | 54.98M | -24.82M | -195.01M | -16.58M | 454.50K |
| Financing Cash Flow | 656.00K | 2.06M | 2.14M | 2.89M | 234.72M | 28.90M | 12.31M |
| Net Change in Cash | -7.82M | -18.62M | 35.44M | -36.72M | 29.03M | 3.54M | 3.96M |
| Free Cash Flow | -36.18M | -29.26M | -25.39M | -33.26M | -14.51M | -10.85M | -10.07M |
This table shows 7 annual periods of MaxCyte's cash flow statement, from FY 2025 back to FY 2019, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MXCT's reporting calendar. What is a cash flow statement?